These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27151992)

  • 1. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Marine J; Miranda M; Azaryan A; Yu X; Nava-Parada P; Mei J; Kipps TJ
    Haematologica; 2016 Jul; 101(7):e295-8. PubMed ID: 27151992
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
    Walter HS; Jayne S; Rule SA; Cartron G; Morschhauser F; Macip S; Karlin L; Jones C; Herbaux C; Quittet P; Shah N; Hutchinson CV; Fegan C; Yang Y; Mitra S; Salles G; Dyer MJS
    Blood; 2017 May; 129(20):2808-2810. PubMed ID: 28377400
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Grant B; Sharman JP; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Sukbuntherng J; Chang BY; Clow F; Hedrick E; Buggy JJ; James DF; O'Brien S
    N Engl J Med; 2013 Jul; 369(1):32-42. PubMed ID: 23782158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
    Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
    N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 10. Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
    Li Y; Ramírez-Valle F; Xue Y; Ventura JI; Gouedard O; Mei J; Takeshita K; Palmisano M; Zhou S
    J Clin Pharmacol; 2017 Oct; 57(10):1279-1289. PubMed ID: 28543084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
    Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
    Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
    Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
    Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
    Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    Mato AR; Timlin C; Ujjani C; Skarbnik A; Howlett C; Banerjee R; Nabhan C; Schuster SJ
    Br J Haematol; 2018 Apr; 181(2):259-261. PubMed ID: 28220935
    [No Abstract]   [Full Text] [Related]  

  • 15. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    Stephens DM
    J Clin Oncol; 2021 Nov; 39(31):3419-3422. PubMed ID: 34310198
    [No Abstract]   [Full Text] [Related]  

  • 17. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
    Molica S
    Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors.
    Dunbar A; Joosse ME; de Boer F; Eefting M; Rijnders BJA
    Neth J Med; 2020 Sep; 78(5):294-296. PubMed ID: 33093256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.